Innovative Eyewear, Inc. income statement LUCY

In fiscal 2025, which ended Dec 31, 2025, Innovative Eyewear, Inc. reported revenue of $2.7 million, up 62.6% from the year before. It recorded a net loss of $7.6 million. Diluted earnings per share were -$1.90. Over the twelve months ended Jun 30, 2026, revenue was $3.4 million and the net loss was $7.7 million. Across the 4 fiscal years shown, revenue grew from $659,788 in fiscal 2022 to $2.7 million in fiscal 2025, about 59.2% a year.

USD in millions, except per-share amounts and margins. The percent under a figure is the change from the year before.

Line
FY 2026
Jun 30, 2026
FY 2025
Dec 31, 2025
FY 2024
Dec 31, 2024
FY 2023
Dec 31, 2023
FY 2022
Dec 31, 2022
Revenue
3
+72.5%
3
+62.6%
2
+42.0%
1
+74.7%
1
Cost of revenue
3
+62.9%
2
+47.4%
1
+11.8%
1
+77.6%
1
Gross profit
1
+115.4%
1
+163.7%
0
+280.3%
-0
-112.0%
-0
Research and development
1
-36.2%
1
-11.5%
1
+23.7%
1
+26.2%
1
Selling, general and administrative
9
+16.2%
8
+14.2%
7
+21.0%
6
+22.2%
5
Net income
-8
+0.6%
-8
+2.3%
-8
-16.6%
-7
-17.3%
-6
Basic EPS
-1.34
+57.3%
-1.90
+63.4%
-5.19
+52.3%
-10.87
—
Diluted EPS
-1.34
+57.3%
-1.90
+63.4%
-5.19
+52.3%
-10.87
—
Weighted average shares, basic
6
+132.7%
4
+166.8%
1
—
—
Weighted average shares, diluted
6
+132.7%
4
+166.8%
1
+144.1%
1
—
Other measures
Depreciation and amortization
0
-44.9%
0
-39.0%
0
+79.2%
0
+176.4%
0
Margins
Gross margin
22.79%
21.32%
13.15%
-10.35%
-8.53%
Profit margin
-225.28%
-285.20%
-474.60%
-578.18%
-861.16%
How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. The first column is the trailing twelve months through the latest quarter. More on our methodology.

Company profile

Industry
Ophthalmic Goods (SIC 3851)
Listed as
LUCY (Nasdaq), LUCYW (Nasdaq)
Fiscal year ends
December 31
Incorporated in
FL
Headquarters
Miami, FL
SEC filer status
, Emerging growth company
SEC CIK
1808377

Other Ophthalmic Goods companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.